Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony

Executive Summary

An upgrade to Abbott's Meridia riskmanagement program means FDA has taken action to strengthen warnings on four of seven drugs flagged by FDA Office of Drug Safety Associate Director David Graham, MD, during the Senate Finance Committee's hearing on Vioxx

You may also be interested in...



Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall

Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said

Related Content

Topics

UsernamePublicRestriction

Register

PS045056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel